[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asthma-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asthma-patients":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,76,108,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100630610","fixed-triple-inhaled-combination-in-asthmatic-patients-in-a-real-life-setting-strength-100630610",false,"NCT07489911","Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)","A Prospective Non-Interventional Real-world Study Assessing the Effectiveness of Extrafine BDP\u002FFF\u002FG HS Single Inhaler Triple Therapy (SITT) on Symptom Scores in Asthma Patients After 6 Months Treatment","STRENGTH","INCLUSION CRITERIA:\n\n* Physician-confirmed clinical diagnosis of asthma according to GINA guidelines and treated for at least 3 years before inclusion\n* Patients ≥ 18 years of age in ambulatory care\n* Uncontrolled asthma according to the physician's clinical assessment despite the use of:\n\n  1. LABA and high dose ICS or\n  2. LABA and high-dose ICS + LAMA multi-inhaler triple therapy for a minimum of three months.\n* Patients who are eligible for the use of Trimbow 172\u002F5\u002F9 μg pMDI according to the SmPC :\n\n  1. at least on exacerbation, requiring systemic (oral or intravenous) corticosteroids in the previous 12 months\n  2. uncontrolled asthma (ACT≤15) or partially controlled asthma (15\\\u003CACT\\\u003C20)\n  3. FEV1\\\u003C80% at baseline\n* Inhaled asthma therapy was changed to Trimbow 172\u002F5\u002F9 μg pMDI no more than 1 week prior to OR on the day of study inclusion\n* Patient provided written, informed consent to study participation\n\nEXCLUSION CRITERIA:\n\n* Participation in any clinical trial within 30 days prior to enrolment\n* Patients hospitalized due to an exacerbation of their asthma within the last 4 weeks prior to enrolment\n* Another respiratory condition, apart from asthma or COPD, that may interfere with the effectiveness of the treatment studied AND\u002FOR another important clinical situation that may interfere with patient's compliance with the treatment.\n* Continuous use of oral (\\>5 mg prednisolone\u002Fday OR \\>4 mg methylprednisolone\u002Fday) OR intravenous corticosteroids\n* Use of continuous oxygen therapy\n* Any malignant disease in the last 5 years\n* Tuberculosis (active or anamnestic)\n* Actual or previous use of biologics for asthma treatment in the past 12 months\n* All exclusion criteria listed in Trimbow 172\u002F5\u002F9 μg pMDI SmPC","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients at GINA steps 4 and 5. Recently, RCTs proved the efficacy and safety of fixed triple combinations of moderate and high dose of ICS and LABA, LAMA in a very selected asthmatic population, resulting in the market authorisation of these products. However, there is a lack of evidence on the real-world effectiveness of these therapies, especially with regards to improvement in symptom scores and adherence.",[25,26,27],"Asthma","Asthma Patients","Asthma Bronchiale",[29,25,30,31],"Single Inhaler Triple Therapy","SITT","Trimbow","RECRUITING","2026-03-18",{"date":35,"type":36},"2026-03-24","ACTUAL",{"date":38,"type":36},"2024-11-04",{"date":40,"type":21},"2026-07",{"name":42,"class":43},"Chiesi Slovenija, d.o.o.","INDUSTRY",18,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100594372","pharmacist-counseling--self-management-program-for-asthma-patients-in-a-midwest-chain-pharmacy-usa-100594372","NCT07018583","Pharmacist Counseling & Self-Management Program for Asthma Patients in a Midwest Chain Pharmacy, USA","The Effectiveness of Pharmacist's Counseling and Self-Management Application Program on Asthma Management Outcomes Among Asthma Patients at a Midwest Chain Pharmacy in Iowa, United States","Inclusion criteria:\n\n1. Adult patients with asthma are 25 - 64 years of age.\n2. Have been receiving medications from the pharmacy of either Inhaled Corticosteroids (ICS) or a fixed combination of ICS with a long-acting beta-agonist (bronchodilator) and regular patronage of the pharmacy for the previous six months.\n3. Confirmed diagnosis from either the physician's diagnosis or the patient's self-report.\n4. No respiratory comorbidities (i.e., COPD or lung diseases).\n5. Uses a smartphone (IOS or Android).\n6. Ability to communicate with the pharmacist in English.\n7. Volunteer to participate in the program for the period.\n\nExclusion criteria:\n\n1. The adult patient with asthma aged \\\u003C 25 years or \\> 64 years old.\n2. The patient with one of the following - coronary heart disease, severe hypertension, severe heart failure, severe musculoskeletal disorder, mental health condition, dementia, chronic obstructive lung disease, or COVID-19.\n3. Participating in another \"Pharmacy Counseling or Education Program.\"\n4. The patient does not have a smartphone (iOS or Android).\n5. The patient does not have sufficient comprehension or the ability to communicate effectively in English.\n6. The patient is unwilling or unable to participate in the entire program.","25 Years","64 Years",{"count":55,"type":21},84,"INTERVENTIONAL",[58],"NA","This clinical trial aims to evaluate the effectiveness of a pharmacist-led counseling and self-management application program on improving asthma management outcomes among adult patients with asthma receiving care at a Midwest chain pharmacy in Iowa, United States.\n\nThe study investigates whether integrating the pharmacist counseling with self-management theory can enhance patients' medication adherence, asthma control, inhaler technique, and overall asthma awareness. These outcomes will be assessed at both 3 and 6 months after enrollment.\n\nParticipants will be randomly assigned to one of two arms. The intervention group, which will receive a comprehensive pharmacist-led counseling program supported by a mobile application (\"Don R.Ph Application\").\n\nThe control group, which will receive standard pharmacy care as per usual practice.",[26],[62,63,64],"Pharmacist-led-intervention","Asthma management","Asthma awareness","NOT_YET_RECRUITING","2025-06-23",{"date":68,"type":36},"2025-06-27",{"date":70,"type":21},"2025-08-01",{"date":72,"type":21},"2026-05-31",{"name":74,"class":75},"Nakhon Ratchasim Rajabhat University","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":56,"phases":87,"briefSummary":88,"conditions":89,"keywords":94,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100594912","effects-of-buteyko-breathing-exercise-in-children-with-uncontrolled-asthma-100594912","NCT07025616","Effects of Buteyko Breathing Exercise in Children With Uncontrolled Asthma","Effectiveness of Buteyko Breathing Exercise in Children With Uncontrolled Asthma: A Single Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Children aged 7-17 years\n2. Uncontrolled or partially controlled asthma (GINA Symptom Control Tool score \\> 1)\n3. Receive bronchodilator therapy, either oral or inhaler from a pediatrician.\n4. Children and parents\u002Fcare givers agree to participate in the study until the end, and parents\u002Fcare givers sign the informed consent form.\n5. Can understand instructions.\n\nExclusion Criteria:\n\n1. Inpatients\n2. Have received Buteyko breathing exercises or other breathing exercises.\n3. Have congenital heart disease, pneumonia, or other significant and uncontrolled health disorders.\n4. Have severe physical disabilities or mental retardation that could potentially prevent the implementation of Buteyko breathing exercises.\n5. Have contraindications for spirometry examination","7 Years","17 Years",{"count":86,"type":21},74,[58],"This randomized controlled trial study aimed to measure the effectiveness of the combination of 4-weeks Buteyko breathing exercises and pharmacological therapy compared with pharmacological therapy alone in children with uncontrolled asthma.",[90,91,92,26,93],"Breathing Techniques","Asthma Control Level","Asthma in Children","Breathing Exercise",[25,95,96,97],"Buteyko","breathing retraining","pediatrics","2025-06-13",{"date":100,"type":36},"2025-06-17",{"date":102,"type":21},"2025-06",{"date":104,"type":21},"2025-12",{"name":106,"class":75},"Ivan Sofian Wibowo",1,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":116,"targetDuration":4,"studyType":56,"phases":118,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":107},"100574965","effectiveness-of-asthma-education-program-based-on-the-roy-adaptation-model-100574965","NCT06766136","Effectiveness of Asthma Education Program Based on the Roy Adaptation Model","The Effect of Education Given to Asthmatic Individuals According to Roy Adaptation Model on Psychosocial Adjustment and Quality of Life","Inclusion Criteria:\n\n* Being in the age range of 18-64\n* Diagnosed with asthma for at least 6 months\n* To live in the city center\n* Asthma control test (ACT) score 24-20 (partial control) or ≤19 (uncontrolled)\n* Patients who voluntarily agreed to participate in the study\n\nExclusion Criteria:\n\n* Has a secondary chronic disease other than asthma\n* Diagnosed with neuropsychiatric illness\n* Individuals with inability to understand or speak Turkish and sensory problems that prevent communication",true,{"count":117,"type":21},36,[58],"The aim of the study; to determine the effect of the education program given to individuals diagnosed with asthma based on Roy's adjustment model on their psychosocial adjustment to the disease and their quality of life.",[26],[122,123,124],"Asthma patient","Psychosocial Adjustment","Life Quality",{"date":126,"type":36},"2025-06-15",{"date":128,"type":36},"2024-12-20",{"date":130,"type":21},"2025-10-01",{"name":132,"class":75},"Nigde Omer Halisdemir University",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":56,"phases":142,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":160},"100584752","the-effect-of-deep-tissue-massage-on-respiratory-parameters-in-people-with-asthma-100584752","NCT06893445","The Effect of Deep Tissue Massage on Respiratory Parameters in People With Asthma","Inclusion Criteria:\n\n* diagnosed with bronchial asthma\n* stable health condition, allowing participation in the study\n* informed consent to participate in the study\n\nExclusion Criteria:\n\n* acute or chronic comorbidities that may affect the results (e.g. COPD, heart failure, cancer)\n* any chest surgery performed within the last 6 months\n* contraindications to massage (e.g. skin infections, wounds)\n* pregnancy\n* participation in other clinical trials in the last 3 months","65 Years",{"count":141,"type":21},40,[58],"Bronchial asthma, as a chronic inflammatory disease of the respiratory tract, significantly reduces the quality of life of patients. Standard treatment includes pharmacotherapy, but a holistic approach, including manual therapies, can support pharmacological therapy, reducing the need for drugs.\n\nThe aim of the research is to verify whether deep tissue massage (DTM) techniques applied to the chest significantly affect respiratory parameters in people with asthma. The study is the next stage of the study conducted on healthy people. After obtaining positive results in the study involving people not suffering from respiratory diseases, the next step is to examine people with, in this case, bronchial asthma. It is important to determine whether the use of this form of manual therapy can bring benefits in the context of improving respiratory functions, reducing respiratory muscle tension and relieving subjective symptoms associated with asthma, such as shortness of breath or limitations in everyday functioning.\n\nThe hypothesis assumes that DTM techniques can have a bigger effect on the respiratory system than classic massage (CM).\n\nThe study is a randomized controlled trial, where participants will be randomly assigned to one of two groups: the study group (subjected to DTM) or the control group (subjected to CM). Before and after the massage intervention, participants will undergo spirometry to assess the changes in respiratory parameters. The obtained data will then be analyzed for effects on respiratory parameters and differences between both groups.",[145,26],"Massage",[147,148,149,150],"deep tissue massage","spirometry","asthma","respiratory parameters","2025-03-18",{"date":153,"type":36},"2025-03-25",{"date":155,"type":21},"2025-07-01",{"date":157,"type":21},"2026-08-28",{"name":159,"class":75},"Jagiellonian University",2]